CHICAGO, Nov. 11, 2022 /PRNewswire/ –The International Society for Heart and Lung Transplantation (ISHLT) is now accepting applications for four research grants to be awarded during the first 2023 grant cycle, which concludes with the announcement of winners at the ISHLT Annual Meeting in Denver in April 2023. Applications for these grants will be accepted […]
Coronary/Structural Heart
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
Oak Ridge, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar – Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and […]
Mediwhale Brings AI-empowered Diagnostic Retina Scans to the United States to Help Prevent Heart and Kidney Diseases
The South Korean, AI diagnostics company aims for FDA approvals to increase non-invasive, early detection to save lives Seoul, South Korea – November 10, 2022 – Mediwhale, the AI-empowered health diagnostics company based in South Korea, made waves in the United States when its scientific teams spoke last week at […]
STRONG-HF study results demonstrate clear benefits for acute heart failure patients
STRONG-HF study primary outcomes showed significant reduction of all cause death or acute heart failure readmissions, at day 180, when the study strategy was implemented Rapid, simultaneous up-titration of therapies, and close follow-up, led to increased patient quality of life. The Roche Elecsys® NT-proBNP biomarker is an integral part of the treatment […]
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers – – Virtual Program Begins at 10am ET Today, Wednesday, November 9th – ANN ARBOR, Mich., Nov. […]
AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented a new analysis […]
Implicity to Participate in Health Tech Challengers Super Finals at HLTH 2022
Company named a Top 8 Super Finalist in the global health tech competition identifying the most disruptive companies shaping the future of digital health. CAMBRIDGE, Mass., Nov. 8, 2022 /PRNewswire/ — Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced it has been selected to participate in the Health […]
SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials
DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented today as Late-Breaking Clinical Science at the American Heart Association (AHA) Scientific Sessions 2022. With this news, Medtronic […]
Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions
LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced results from a preclinical study of […]
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for […]



